Clinical trials: Severe Acute Pancreatitis
Acute Pancreatitis, Intestinal Bacteria Flora Disturbance
Fecal Microbiota Transplantation for Pancreatitis
The intestinal microbiota plays a pivotal role in the maintenance of intestinal homeostasis and protecting the gut against pathogens by competing for nutrients, creating the intestinal biological barrier and modulating the host…
- Conditions
- Acute Pancreatitis, Intestinal Bacteria Flora Disturbance, Intestinal Dysfunction, Fecal Microbiota Transplantation
- Trial name
- FMTP (NCT02318134)
- Testing
- Fecal Microbiota Transplantation, normal saline
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Hypertriglyceridemia
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL)…
- Trial name
- NCT04863014
- Testing
- evinacumab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 21 people
- Sponsor
- Regeneron Pharmaceuticals
Pancreatitis, Acute
Safety and Tolerability of Pirfenidone in Acute Pancreatitis
The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis.
- Trial name
- NCT05350371
- Testing
- Pirfenidone Oral Tablet
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Acute Pancreatitis
Pentoxifylline Treatment of Acute Pancreatitis
The purpose of this study is to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis, to see if it can improve blood tests associated with inflammation (tissue damage).
- Trial name
- NCT01292005
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Severe Hypertriglyceridemia (sHTG)
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
- Trial name
- NCT03452228
- Testing
- evinacumab
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals